Author
Berkeley Law Life Sciences Law & Policy Center Director Vincent Joralemon recently sat down with Sofia Palmieri, a health law scholar working at the intersection of medicine, artificial intelligence, and regulation on both sides of…
Berkeley Law Life Sciences Law & Policy Center Director Vincent Joralemon recently sat down with Javier R. Mesa, a public defender turned behavioral neuroscientist whose work sits at the intersection of law and neuroscience.
When AI chatbots are asked about mixing substances, managing withdrawal, or reducing overdose risk, they increasingly provide substantive guidance.
Psilocybin should be regulated under food law rather than drug law. Doing so would serve public health, individual autonomy, and regulatory coherence.
President Trump’s recent executive order directing federal agencies to finalize the rescheduling of cannabis from Schedule I to Schedule III marks a watershed moment in American drug policy.
By Vincent Joralemon Pharmaceutical advertisers want health data so that they can effectively tailor the $18 billion spent annually on drug pitches to those audiences most likely to buy these products. However, a recent privacy…
By Vincent Joralemon As therapies using drugs like MDMA, psilocybin, and LSD advance through the FDA research and approval pipeline, patients should be prepared for steep price tags attached to these procedures. For example, experts…
FDA rescheduling may provide a compelling model for efforts to decriminalize and destigmatize other substances moving forward.
Lykos’ current application is based on MDMA-assisted therapy, and FDA will almost surely require that patients take the drug in a clinical setting.
The telemedicine extension is not just for psychedelics; easing these restrictions means relaxing them for other controlled substances as well.
